Liposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Sousa, Sofia ^a   Auriola, Seppo ^a   Mönkkönen, Jukka ^a   Määttä, Jorma ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Bisphosphonates; Breast Cancer; Clodronate; Cytokines; Liposomes; Tumour associated Macrophages; Zoledronate

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOSOME; MATRIX METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CONDITIONED MEDIUM; IMIDAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CELL ACTIVATION; CELL CULTURE; CELL GROWTH; CELL INFILTRATION; CELL POLARITY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION PROFILING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SECRETION; SPECTROPHOTOMETRY; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CONDITIONED MEDIUM; CYTOLOGY; DRUG EFFECTS; FEMALE; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHARMACOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LIPOSOMES; MACROPHAGES; MATRIX METALLOPROTEINASES; MICE; NITRIC OXIDE SYNTHASE TYPE II; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84938856168     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1005-7     Document Type: Article

References (52)

1. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677-86.
2. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231-7.
3. Wang T, Ge Y, Xiao M, Lopez-Coral A, Azuma R, Somasundaram R, et al. Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigm Cell Melanoma Res. 2012;25(4):493-505.
4. Klug F, Prakash H, Huber P, Seibel T, Bender N, Halama N, et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24(5):589-602.
5. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65(8):3437-46.
6. Klimp AH, de Vries EGE, Scherphof GL, Daemen T. A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol. 2002;44(2):143-61.
7. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25(3):315-22.
8. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549-55.
9. Su S, Liu Q, Chen J, Chen J, Chen F, He C, et al. A Positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell. 2014;25(5):605-20.
10. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71-8.
11. Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl Med. 2011;9:177-5876-9-177.
12. Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol. 2006;69(5):1624-32.
13. Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011;49(1):34-41.
14. Auriola S, Frith J, Rogers MJ, Koivuniemi A, Mönkkönen J. Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Appl. 1997;704(1-2):187-95.
15. Mitrofan LM, Pelkonen J, Mönkkönen J. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. Bone. 2009;45(6):1153-60.
16. Roelofs AJ, Jauhiainen M, Mönkkönen H, Rogers MJ, Mönkkönen J, Thompson K. Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol. 2009;144(2):245-50.
17. Mönkkönen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsäläinen J, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol. 2006;147(4):437-45.
18. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007;67(23):11438-46.
19. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010;14(12):2803-15.
20. Mönkkönen J, Valjakka R, Hakasalo M, Urtti A. Optimization of liposome formulation for the delivery of clodronate to cells in vitro. Proc Control Release Soc. 1994;21:224-5.
21. Bartlett GR. Colorimetric assay methods for free and phosphorylated glyceric acids. J Biol Chem. 1959;234(3):469-71.
22. Nargi FE, Yang TJ. Optimization of the L-M cell bioassay for quantitating tumor necrosis factor alpha in serum and plasma. J Immunol Methods. 1993;159(1-2):81-91.
23. Martinez FO. Regulators of macrophage activation. Eur J Immunol. 2011;41(6):1531-4.
24. Mönkkönen H, Moilanen P, Mönkkönen J, Frith JC, Rogers MJ, Auriola S. Analysis of an adenine nucleotide-containing metabolite of clodronate using ion pair high-performance liquid chromatography-electrospray ionisation mass spectrometry. J Chromatogr B Biomed Sci Appl. 2000;738(2):395-403.
25. Räikkönen J, Mönkkönen H, Auriola S, Mönkkönen J. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem Pharmacol. 2010;79(5):777-83.
26. Anne-Valérie R, Christelle D, Yannick F, Norbert P, Marc P, Dominique H. Human growth hormone stimulates proteinase activities of rabbit bone cells via IGF-I. Biochem Biophys Res Commun. 2000;268(3):875-81.
27. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365-86.
28. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques. 2002;32(6):1372. -4, 1376, 1378-9.
29. Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(β, γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 1997;12(9):1358-67.
30. MacMicking J, Xie Q, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997;15:323-50.
31. Ellies LG, Fishman M, Hardison J, Kleeman J, Maglione JE, Manner CK, et al. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int J Cancer. 2003;106(1):1-7.
32. Lin C, Shen S, Ko C, Lin H, Chen Y. Reciprocal activation of macrophages and breast carcinoma cells by nitric oxide and colony-stimulating factor-1. Carcinogenesis. 2010;31(12):2039-48.
33. Gallet M, Mentaverri R, Sévenet N, Brazier M, Kamel S. Ability of breast cancer cell lines to stimulate bone resorbing activity of mature osteoclasts correlates with an anti-apoptotic effect mediated by macrophage colony stimulating factor. Apoptosis. 2006;11(11):1909-21.
34. Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res. 2001;100(1):18-24.
35. Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005;65(12):5278-83.
36. Neumark E, Sagi-Assif O, Shalmon B, Ben-Baruch A, Witz IP. Progression of mouse mammary tumors: MCP-1-TNFaα cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int J Cancer. 2003;106(6):879-86.
37. Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-aα dependent up-regulation of matrix metalloproteases. Carcinogenesis. 2004;25(8):1543-9.
38. Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res. 2002;62(23):7042-9.
39. Randow F, Syrbe U, Meisel C, Krausch D, Zuckermann H, Platzer C, et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med. 1995;181(5):1887-92.
40. Pennanen N, Lapinjoki S, Urtti A, Mönkkönen J. Effect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNFaα secretion from RAW 264 cells in vitro. Pharm Res. 1995;12(6):916-22.
41. Mönkkönen J, Similä J, Rogers MJ. Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sci. 1998;62(8):L95-PL102.
42. Makkonen N, Hirvonen M, Teräväinen T, Savolainen K, Mönkkönen J. Different effects of three bisphosphonates on nitric oxide production by RAW 264 macrophage-like cells in vitro. J Pharmacol Exp Ther. 1996;277(2):1097-102.
43. Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int. 1997;61(5):386-92.
44. Töyräs A, Ollikainen J, Taskinen M, Mönkkönen J. Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. Eur J Pharm Sci. 2003;19(4):223-30.
45. Takagi K, Takagi M, Kanangat S, Warrington KJ, Shigemitsu H, Postlethwaite AE. Modulation of TNF-aα gene expression by IFN-γ and pamidronate in murine macrophages: regulation by STAT1-dependent pathways. J Immunol. 2005;174(4):1801-10.
46. Carbone LD, Warrington KJ, Barrow KD, Pugazhenthi M, Watsky MA, Somes G, et al. Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol. 2006;146(3):371-80.
47. Makkonen N, Salminen A, Rogers MJ, Frith JC, Urtti A, Azhayeva E, et al. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur J Pharm Sci. 1999;8(2):109-18.
48. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, et al. TNFerade biologic, an Adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004;22(4):592-601.
49. Valleala H, Hanemaaijer R, Mandelin J, Salminen A, Teronen O, Mönkkönen J, et al. Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates. Life Sci. 2003;73(19):2413-20.
50. Teronen O, Heikkilä P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, et al. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci. 1999;878(1):453-65.
51. Leifler KS, Svensson S, Abrahamsson A, Bendrik C, Robertson J, Gauldie J, et al. Inflammation induced by mmp-9 enhances tumor regression of experimental breast cancer. J Immunol. 2013;190(8):4420-30.
52. Wyckoff JB, Wang Y, Lin EY, Li J, Goswami S, Stanley ER, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67(6):2649-56.